Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dreieich – page 120

1 481 clinical trials in Dreieich, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dreieich at a glance
1 481
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 481 trials in Dreieich

Open in trial search

Study of RO7247669 and Nab-Paclitaxel vs. Pembrolizumab and Nab-Paclitaxel for Patients with Untreated, PD-L1 Positive, Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Food allergy

Not recruiting

Study on Long-Term Safety of Ligelizumab for Patients with Food Allergies

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Epinephrine
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Alopecia areata

Not recruiting

Study on Baricitinib for Treating Children Aged 6 to 17 with Alopecia Areata

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Bronchiectasis

Not recruiting

Study on Long-Term Safety and Efficacy of BI 1291583 in Patients with Bronchiectasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Diabetic retinopathy

Not recruiting

Study on BI 764524 for Patients with Moderate to Severe Diabetic Retinopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 764524
  • Sponsor:Boehringer Ingelheim International GmbH

Study on the Effects and Safety of Belimumab for Adults with Early Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study of Asciminib Treatment for Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Oncolytics Biotech Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dreieich

What the registry says about research in the country

01 Allergy Research

Clinical trials focusing on innovative treatments for allergic rhinoconjunctivitis, particularly targeting birch pollen and house dust mite allergies.

  • Birch Pollen Allergies
  • House Dust Mite Sensitivity
  • Immunotherapy Development

Research includes evaluation of subcutaneous immunotherapy treatments and novel allergoid formulations.

02 Pediatric Allergology

Dedicated studies examining the safety and efficacy of STALORAL® treatments in children and adolescents with seasonal allergies.

  • Child-Specific Treatments
  • Age-Appropriate Dosing
  • Safety Monitoring

Special focus on developing safe and effective treatments for young patients aged 5-17 years.

03 Respiratory Medicine

Comprehensive research into moderate to severe allergic conditions affecting the respiratory system, including asthma complications.

  • Combined Symptom Management
  • Therapeutic Efficacy
  • Long-term Treatment Outcomes

Studies evaluate both symptomatic relief and long-term disease modification approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.